SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Provided By GlobeNewswire
Last update: Nov 6, 2024
Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness.
The company remains on track for a topline Phase 1 data readout by the end of the year.
Read more at globenewswire.comNASDAQ:SABSW (2/21/2025, 8:00:01 PM)
0.0263
0 (-12.33%)
1.82
-0.13 (-6.67%)
Find more stocks in the Stock Screener
